2019
DOI: 10.4103/njcp.njcp_495_18
|View full text |Cite
|
Sign up to set email alerts
|

Up-regulation of hypoxia inducible Factor-1α in patients with diabetic nephropathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…TAB1/TAK1 can activate nuclear factor κB (NF-κB) in high glucose (HG)-induced BMMs, regulating macrophage activation [8][9][10][11][12]. Studies suggest that activation of the NF-κB signaling pathway upregulates HIF-1α activity and enhances glycolytic metabolism in an autonomous fashion, HIF-1α may be considered as a novel therapeutic target for DN [13][14][15][16]. HIF-1α has been reported to be closely involved in energy metabolism and it increases the activity of glycolytic enzymes such as hexokinase-1 (HK1), 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) and lactate dehydrogenase A (LDHA) [17,18].…”
Section: Introductionmentioning
confidence: 99%
“…TAB1/TAK1 can activate nuclear factor κB (NF-κB) in high glucose (HG)-induced BMMs, regulating macrophage activation [8][9][10][11][12]. Studies suggest that activation of the NF-κB signaling pathway upregulates HIF-1α activity and enhances glycolytic metabolism in an autonomous fashion, HIF-1α may be considered as a novel therapeutic target for DN [13][14][15][16]. HIF-1α has been reported to be closely involved in energy metabolism and it increases the activity of glycolytic enzymes such as hexokinase-1 (HK1), 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) and lactate dehydrogenase A (LDHA) [17,18].…”
Section: Introductionmentioning
confidence: 99%